Camostat and E-64d need to be fast-tracked for clinical trials

These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics).

Camostat Mesylate / Camostat / 59721-29-8

- 100-200 mg p.c. (300-600 mg/daily)

- Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis

E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9

- Possibly 100-150 mg p.c. (300-450mg/daily)

- May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood

- Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis